Jul 15
|
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
|
Jul 14
|
HER2+ Gastric Cancer Market Analysis and Forecast Report 2025-2035: AstraZeneca, Merck, and Roche Lead Innovation in HER2+ Gastric Cancer Therapies
|
Jul 14
|
Myopic Macular Degeneration Market Analysis and Forecast Report 2025-2035 | Advancements in Anti-VEGF Therapies Driving Progress in Treatments
|
Jul 12
|
FDA willing to trade faster drug reviews for lower prices, Bloomberg reports
|
Jul 11
|
Smart Money Going in Senior Health: Key Stocks in Elderly Care
|
Jul 10
|
Parse-Enabled Study Maps Neuronal Pathways with Potential Implications for Neurodegenerative Disease Research
|
Jul 10
|
Diagnostics Transformed: $37 Billion Immunoassay Market Evolves with AI, Miniaturization, and POC Growth, reports Kalorama Information
|
Jul 10
|
Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 | Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways
|
Jul 10
|
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
|
Jul 9
|
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
|
Jul 9
|
Trump's Drug Tariffs: Where Does the U.S. Import Pharmaceuticals From?
|
Jul 9
|
Biomarkers Market Research Report 2025-2030 | Assay Kit Demand Surges as Advancements in Omics Technologies Elevate Biomarker Discovery and Diagnostic Precision
|
Jul 2
|
Hologic Faces Molecular Drag, But Here's Why It's Not a Major Concern
|
Jun 30
|
Changes to the Roche Enlarged Corporate Executive Committee
|
Jun 27
|
Initiation of commercialization of ProNephro AKI (NGAL) for diagnostic use in the US
|
Jun 26
|
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
|
Jun 26
|
Innovation in Focus: Highlights from the Two-Day London Biotechnology Show 2025
|
Jun 25
|
96% of health care executives are "ready and resourced" to use digital health solutions, yet two-thirds say interoperability is "a tough but manageable challenge," reveals new MIT Technology Review Insights report
|
Jun 23
|
Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug
|
Jun 23
|
Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
|